CISPLATIN INJECTION
As listed in the register: CISPLATIN INJECTION
1 mg · solution
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Cisplatin
- Made by
- Fresenius Kabi Canada Ltd
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Cisplatin). It describes the substance, not this exact product.
The main mechanism of the cytotoxic action involves the binding of cisplatin to genomic DNA in the cell nucleus to form interstrand and intrastrand cross-links.
This interferes with normal transcription and/or DNA replication mechanisms and triggers cytotoxic processes that lead to cell death.
Over a dose range of 40 mg to 140 mg cisplatin per m 2 given as a bolus injection or as infusions varying in length from 1 hour to 24 hours, from 10% to about 40% of the administered platinum is excreted in the urine in 24 hours.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-06-24
Safety of the active substance
From the US prescribing label for the same active substance (Cisplatin). It describes the substance, not this exact product.
WARNING: NEPHROTOXICITY, PERIPHERAL NEUROPATHY, NAUSEA AND VOMITING and MYELOSUPPRESSION..
- Cisplatin for injection is contraindicated in patients with severe hypersensitivity to cisplatin [see Warnings and Precautions ( 5.4 )].
- Severe hypersensitivity to cisplatin ( 4 )
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Fresenius Kabi Canada Ltd |
|---|---|
| Active substance | Cisplatin |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 1 mg |
| Form | solution |
| Classification | L01XA01 · Cancer treatments and immune-system medicines |
| Route | intravenous |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Approved |
| Marketed | No — authorised but not currently marketed, according to the register |
| DIN | 02409186 |
| DPD drug code | 89390 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
5 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- solution5 products
1 mg4
1 mg · 4 companies
- Accord Healthcare Inc
- Fresenius Kabi Canada Ltd · this page
- Omega Laboratories Limited
- Strides Pharma Canada Inc
- 1.0 mg
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.